Publications by authors named "Stephan De Wit"
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
EClinicalMedicine
February 2024
Article Synopsis
- The study examined whether Mas-receptor activation by BIO101 could help balance the Renin-Angiotensin System and reduce severe respiratory issues in hospitalized COVID-19 patients.
- It was a double-blind, randomized trial involving 238 participants, with findings showing a 11.4% lower rate of respiratory failure or early death in the BIO101 group compared to placebo.
- Results suggest BIO101 may reduce the risk of severe outcomes in COVID-19 patients, although further research is needed due to the low sample size.
Background: Antiretroviral (ART) drugs have been associated with higher triglycerides (TG), higher total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) levels. Associations between lipid levels with HIV viraemia and immunosuppression in the presence of ART remain unclear.
Methods: Participants from the D:A:D study with at least one TG/TC/HDL-C measurement were included.
Introduction: There is a lack of data on potential gender differences in the use of interventions to prevent and treat cardiovascular disease (CVD) in HIV-positive individuals. We investigated whether such differences exist in the D:A:D study.
Materials And Methods: Follow-up was from 01/02/99 until the earliest of death, 6 months after last visit or 01/02/13.
Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies.
Design: Baseline data from 17,852 subjects enrolled in DAD, a prospective multinational cohort study initiated in 1999.
Methods: Cross-sectional analyses of CVD risk factors at baseline.